1. European Down Syndrome Association (EDSA) - http://www.edsa.eu/ 2. “Pediatria: principi e pratica clinica” di Bartolozzi
3. Associazione Onlus Trisomia 21 - http://at21.it/chi-aiutiamo/la-sindrome-di-down/ 4. Associazione Italiana Persone Down (AIPD) - https://aipd.it/aipd_salute/
5. “Le basi patologiche delle malattie” di Robbins e Cotran
6. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update; Neha Bhatnagar & Laure Nizery & Oliver Tunstall & Paresh Vyas & Irene Roberts
7. Genetics Home Reference - https://ghr.nlm.nih.gov/gene/GATA1
8. Wechsler J, Greene M, McDevitt M, Anastasi J, Karp J, Le Beau M, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52 9. NCBI Gene https://www.ncbi.nlm.nih.gov/gene/2623
10. https://ghr.nlm.nih.gov/gene/GATA1#location
11. http://mcb.asm.org/content/25/4/1215/F6.expansion.html
12. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–9. This paper provides the first comprehensive analysis of the molecular landscapte of ML-DS and TAM.
13. Nikolaev S, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood. 2013;122:554–61.
14. Khan, S. Malinge, J. Crispino, Myeloid leukemia in Down syndrome, Crit. Rev. Oncog. 16 (2011) 25– 36.
15. J.H. Klusmann, F.J. Godinho, K. Heitmann, A. Maroz, M.L. Koch, D. Reinhardt, S.H.Orkin, Z. Li, Developmental stage-specific interplay of GATA1 and IGF signalling in fetal megakaryopoiesis and leukemogenesis, Genes Dev. 24 (2010) 1659–1672.
16. Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, et al. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of prospective multi-centre Oxford Imperial Down syndrome cohort study which showed the high frequency of acquired GATA1 mutations in neonates with Down syndrome and described Silent TAM for the first time.
17. Rao A, Hills R, Stiller C, Gibson B, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2006;132:576–83. 46. Webb D, Roberts I, Vyas P. Haematology of Down syndrome. Arch Dis Child Fetal Neonatal Ed. 2007;92:503–7.
83 18. Acute leukemias in children with Down syndrome- Laura Seewald, Jeffrey W. Taub, Kelly W.
Maloney, Edward R.B. McCabe
19. https://www.ncbi.nlm.nih.gov/gene/64109
20. http://www.geneticapediatrica.it/archivi/2010/archivio1/explorer.php?id=8
21. D. Bercovich, I. Ganmore, L.M. Scott, G. Wainreb, Y. Birger, A. Elimelech, C. Shochat, G. Cazzaniga, A. Biondi, G. Basso, G. Cario, M. Schrappe, M. Stanulla, S. Strehl, O.A. Haas, G. Mann, V. Binder, A. Borkhardt, H. Kempski, J. Trka, B. Bielorei, S. Avigad, B. Stark, O. Smith, N. Dastugue, J.P. Bourquin, N.B. Tal, A.R. Green, S. Izraeli, Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome, Lancet 372 (2008) 1484–1492.
22. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with down syndrome P Lee, R Bhansali, S Izraeli, N Hijiya, J D Crispino
23. K.W. Maloney, W.L. Carroll, A.J. Carroll, M. Devidas, M.J. Borowitz, P.L. Martin, J. Pullen, J.A. Whitlock, C.L. Willman, N.J. Winick, B.M. Camitta, S.P. Hunger, Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group, Blood 116 (2010) 1045–1050
24. C.H. Pui, S.C. Raimondi, M.J. Borowitz, V.J. Land, F.G. Behm, D.J. Pullen, M.L. Hancock, J.J. Shuster, C.P. Steuber, W.M. Crist, et al., Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia, J. Clin. Oncol. 11 (1993) 1361–1367. 25. S. Izraeli, The acute lymphoblastic leukemia of Down Syndrome – Genetics and Pathogenesis,
European Journal of Medical Genetics (2015), doi: 10.1016/j.ejmg.2015.11.010. 26. https://en.wikipedia.org/wiki/HMGN1
27. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Daniel A. Arber, Attilio Orazi, Robert Hasserjian, J¨urgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola and James W. Vardiman
28. “Pediatria” di Nelson
29. Protocollo AIEOP LAM 2002/02 – S. Di Down
30. Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia Erik Hefti, PharmD, MS and Javier G. Blanco, PhD
31. S. Malinge, S. Izraeli, J.D. Crispino, Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome, Blood 113 (2009) 2619–2628.
32. http://www.ospedalebambinogesu.it/leucemia-acuta-mieloide#.WppS9VTOVPY
33. Down Syndrome, Drug Metabolism, and Chromosome 21 Jeffrey W. Taub1,2,3* and Yubin Ge1 34. Protocollo AIEOP 2009 ALL
35. https://www.burlo.trieste.it/leucemia-linfoblastica-acuta- IRCCS materno infantile Burlo Garofolo Regione Friuli Venezia Giulia
84 37. https://www.ematologiainprogress.it/leucemia-acuta-linfoide/
38. www.wikipedia.com-Antracicline
39. Taub JW, Matherly LH, Stout ML, et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood. 1996;87:3395–3403.
40. Down Syndrome, Drug Metabolism, and Chromosome 21 Jeffrey W. Taub1,2,3* and Yubin Ge1 41. Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrom: A
Literature Review Erik Hefti and Javier G. Blanco*. Department of Pharmaceutical Sciences, The School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York, United States of America
42. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin- Frankfurt-Munster Group. Leukemia. 1998;12:645-651.
43. SEEWALD - Acute leukemias in children with down syndrome 44. https://en.wikipedia.org/wiki/Fludarabine
https://it.wikipedia.org/wiki/Vincristina 45. https://en.wikipedia.org/wiki/Asparaginase
46. AIMAC - https://www.favo.it/profilo-associazione/aimac.html
47. How I treat ALL in Down’s syndrome: pathobiology and management Shai Izraeli,1 Ajay Vora,2 C. Michel Zwaan,3 and James Whitlock4
48. W. Stock, D. Yu, B. Sanford, G. Lozanski, R. Vij, J.C. Byrd, B.L. Powell, M. Wetzler, D. Sher, C. Edwards, M. Kelly, S.M. Richards, C. Sung, G. Malnassy, E. Hoke, C.D. Bloomfield, R.A. Larson, Alemtuzumab can be Incorporated into Front-line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102) ASH Annual Meeting Abstracts, 51st ASH Annual Meeting and Exposition, 2009.
49. E.A. Raetz, M.S. Cairo,M.J. Borowitz, S.M. Blaney,M.D. Krailo, T.A. Leil, J.M. Reid, D.M. Goldenberg, W.A. Wegener, W.L. Carroll, P.C. Adamson, Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study, J. Clin. Oncol. 26 (2008) 3756–3762
50. Fonte di alcune immagini: Google immagini
51. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia; Claudia Scholl Richard F. Schlenk Karina Eiwen Hartmut Döhner Stefan Fröhling Konstanze Döhner for the AML Study Group